Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

A New Active Vitamin D, ED-71, Increases Bone Mass in Osteoporotic Patients under Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

A New Active Vitamin D, ED-71, Increases Bone Mass in Osteoporotic Patients under Vitamin D... AbstractContext: ED-71 has been shown to increase lumbar bone mineral density (BMD) in osteoporotic subjects. However, vitamin D insufficiency might have influenced the effect of ED-71 on BMD.Objective: Our objective was to examine whether ED-71 can increase BMD in osteoporotic patients under vitamin D supplementation.Design, Setting, and Patients: We conducted a randomized, double-blind, placebo-controlled clinical trial of 219 osteoporotic patients (49–87 yr of age).Interventions: Subjects were randomly assigned to receive placebo or 0.5, 0.75, or 1.0 μg/d ED-71 for 12 months. All the subjects received 200 or 400 IU/d vitamin D3.Main outcome measures: We assessed changes in lumbar and hip BMD and bone turnover markers from baseline.Results: Lumbar BMD increased with ED-71 treatment for 12 months (2.2, 2.6, and 3.1% from baseline and 2.9, 3.4, and 3.8% vs. placebo group in subjects receiving 0.5, 0.75, and 1.0 μg ED-71, respectively). Total hip BMD also increased with 0.75 and 1.0 μg ED-71 (−0.8, 0.6, and 0.9% from baseline and 0.1, 1.5, and 1.8% vs. placebo group in the 0.5, 0.75, and 1.0 μg ED-71 groups, respectively). Bone formation and resorption markers were suppressed by approximately 20% after 12 months of 0.75 and 1.0 μg ED-71 treatment. Transient hypercalcemia over 2.6 mmol/liter occurred in 7, 5, and 23% of subjects in the 0.5, 0.75, and 1.0 μg ED-71 groups, respectively, but none of them developed sustained hypercalcemia.Conclusions: These results demonstrate that ED-71 treatment at around 0.75 μg/d can effectively and safely increase lumbar and hip BMD in osteoporotic patients with vitamin D supplementation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

A New Active Vitamin D, ED-71, Increases Bone Mass in Osteoporotic Patients under Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Download PDF
6 pages

Loading next page...
 
/lp/oxford-university-press/a-new-active-vitamin-d-ed-71-increases-bone-mass-in-osteoporotic-SEM1WQ8s0D

References (18)

Publisher
Oxford University Press
Copyright
Copyright © 2005 by The Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
DOI
10.1210/jc.2004-2552
pmid
15972580
Publisher site
See Article on Publisher Site

Abstract

AbstractContext: ED-71 has been shown to increase lumbar bone mineral density (BMD) in osteoporotic subjects. However, vitamin D insufficiency might have influenced the effect of ED-71 on BMD.Objective: Our objective was to examine whether ED-71 can increase BMD in osteoporotic patients under vitamin D supplementation.Design, Setting, and Patients: We conducted a randomized, double-blind, placebo-controlled clinical trial of 219 osteoporotic patients (49–87 yr of age).Interventions: Subjects were randomly assigned to receive placebo or 0.5, 0.75, or 1.0 μg/d ED-71 for 12 months. All the subjects received 200 or 400 IU/d vitamin D3.Main outcome measures: We assessed changes in lumbar and hip BMD and bone turnover markers from baseline.Results: Lumbar BMD increased with ED-71 treatment for 12 months (2.2, 2.6, and 3.1% from baseline and 2.9, 3.4, and 3.8% vs. placebo group in subjects receiving 0.5, 0.75, and 1.0 μg ED-71, respectively). Total hip BMD also increased with 0.75 and 1.0 μg ED-71 (−0.8, 0.6, and 0.9% from baseline and 0.1, 1.5, and 1.8% vs. placebo group in the 0.5, 0.75, and 1.0 μg ED-71 groups, respectively). Bone formation and resorption markers were suppressed by approximately 20% after 12 months of 0.75 and 1.0 μg ED-71 treatment. Transient hypercalcemia over 2.6 mmol/liter occurred in 7, 5, and 23% of subjects in the 0.5, 0.75, and 1.0 μg ED-71 groups, respectively, but none of them developed sustained hypercalcemia.Conclusions: These results demonstrate that ED-71 treatment at around 0.75 μg/d can effectively and safely increase lumbar and hip BMD in osteoporotic patients with vitamin D supplementation.

Journal

Journal of Clinical Endocrinology and Metabolism – Oxford University Press

Published: Sep 1, 2005

There are no references for this article.